Controlling cancer through the autotaxin–lysophosphatidic acid receptor axis
Biochemical Society Transactions2012Vol. 40(1), pp. 31–36
Citations Over TimeTop 10% of 2012 papers
Mari Gotoh, Yuko Fujiwara, Junming Yue, Jianxiong Liu, Sue-Chin Lee, James I. Fells, Ayako Uchiyama, Kimiko Murakami‐Murofushi, Stephen J. Kennel, Jonathan S. Wall, Renukadevi Patil, Renuka Gupte, Louisa Balázs, Duane D. Miller, Gábor Tigyi
Abstract
LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
Related Papers
- → The Role of Autotaxin and LPA Signaling in Embryonic Development, Pathophysiology and Cancer(2023)11 cited
- → Measurement of lysophospholipase D/autotaxin activity in human serum samples(2006)61 cited
- → Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency(2018)50 cited
- → Distinct contributions of two choline-producing enzymatic activities to lysophosphatidic acid production in human amniotic fluid from pregnant women in the second trimester and after parturition(2020)4 cited
- → Lysophospholipase D/Autotaxin in Lysophospholipid Biology(2007)